The use of psychedelic-assisted therapy to treat cancer-related conditions has come a long way. Recently, several clinical studies have been set up to assess different kinds of treatment, including LSD microdosing and psilocybin for palliative care and cancer-related distress

One of them, a Phase 2 study conducted by Sunstone Therapies, published initial results of psilocybin’s long-term efficacy in cancer patients with Major Depressive Disorder (MDD) in the JAMA Oncology journal back in April.

That data corresponded to an 8-week follow-up period. In June, Sunstone will present its 18-month follow-up outcomes at the American Society for Clinical Oncology (ASCO) meeting. Its importance relies on the fact that it is possibly the longest follow-up data ever generated for a psilocybin study.

The open-label study assessed 25mg of COMPASS Pathways’ (NASDAQ: CMPS) synthetic psilocybin provided to 30 patients with curable and incurable cancer in adjacent rooms in a one-on-one therapist/patient ratio. Preparation and administration sessions were collective and supplemented by individual therapy.

Meanwhile, the University of Washington and psychedelics philanthropist Steven and Alexandra Cohen Foundation are sponsoring a new …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.